<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00683111</url>
  </required_header>
  <id_info>
    <org_study_id>HKEC-2007-176</org_study_id>
    <nct_id>NCT00683111</nct_id>
  </id_info>
  <brief_title>Prevention of Gastrointestinal Bleeding in Patients With Severe Ischemic Heart Disease</brief_title>
  <official_title>Famotidine Compared With Esomeprazole in the Prevention of Ulcer Complications in Patients With Acute Coronary Syndrome or Myocardial Infarction</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ruttonjee Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ruttonjee Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Aspirin and clopidogrel +/- heparin or thrombolytic co-therapy is well established and
      effective treatment for unstable cardiac patients. However, the major complication was
      gastrointestinal bleeding (GIB) due to peptic ulcer. In the prevention of GIB, anti-ulcer
      drug either H2-receptor antagonist (H2RA) and proton pump inhibitor (PPI) were commonly
      prescribed. There has been no prospective controlled study to compare the efficacy of these
      two classes of anti-ulcer drugs.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2008</start_date>
  <completion_date type="Actual">December 2011</completion_date>
  <primary_completion_date type="Actual">December 2011</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>ulcer complication (bleeding/perforation/obstruction)</measure>
    <time_frame>up to 12 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Termination of anti-ischemic drug due to ulcer complications; TIMI severity of GI bleeding; Major adverse cardiac event (composite of death from CV causes, recurrent nonfatal MI, or stroke);</measure>
    <time_frame>up to 12 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Acute Coronary Syndrome</condition>
  <condition>Acute Myocardial Infarction</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>oral esomeprazole 20 mg daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>oral famotidine 40mg daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>esomeprazole 20 mg daily</intervention_name>
    <description>oral famotidine 40 mg daily vs. oral esomeprazole 20 mg daily for up to 12 months</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>famotidine 40 mg daily</intervention_name>
    <description>oral famotidine 40 mg daily vs. oral esomeprazole 20 mg daily for up to 12 months</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  patients admitted for acute coronary syndrome or acute myocardial infarction requiring
             active treatment with aspirin clopidogrel and (enoxaparin or thrombolytics.)

        Exclusion Criteria:

          -  known active peptic ulcer disease or gastrointestinal within 8 wk

          -  known iron deficiency anemia with Hb &lt; 10 gm/dl

          -  mechanical ventilation

          -  active cancer, liver cirrhosis, end-stage renal failure

          -  life expectancy &lt; 1 yr

          -  known allergic to aspirin, clopidogrel, enoxaparin famotidine or esomeprazole

          -  pregnancy, lactation, child-bearing potential in the absence of contraception,

          -  co-prescription of NSAID, corticosteroid, or warfarin

          -  non-oral feeding or impaired GI absorption e.g. vomiting

          -  already on proton pump inhibitor for &gt; 1 day or another clinical trial drug for ulcer
             disease
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Fook Hong Ng, MBBS</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ruttonjee Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Ruttonjee Hospital</name>
      <address>
        <city>Hong Kong</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>June 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 21, 2008</study_first_submitted>
  <study_first_submitted_qc>May 22, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 23, 2008</study_first_posted>
  <last_update_submitted>June 5, 2012</last_update_submitted>
  <last_update_submitted_qc>June 5, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 6, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ruttonjee Hospital</investigator_affiliation>
    <investigator_full_name>Fook-Hong Ng</investigator_full_name>
    <investigator_title>SMO</investigator_title>
  </responsible_party>
  <keyword>acute coronary syndrome</keyword>
  <keyword>acute myocardial infarction</keyword>
  <keyword>aspirin</keyword>
  <keyword>clopidogrel</keyword>
  <keyword>heparin</keyword>
  <keyword>thrombolytic</keyword>
  <keyword>famotidine</keyword>
  <keyword>esomeprazole</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Infarction</mesh_term>
    <mesh_term>Myocardial Infarction</mesh_term>
    <mesh_term>Acute Coronary Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Esomeprazole</mesh_term>
    <mesh_term>Famotidine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

